trending Market Intelligence /marketintelligence/en/news-insights/trending/zEY5-NWy2mVqoX5NC-k6Xg2 content esgSubNav
In This List

Johnson & Johnson secures US FDA priority review for prostate cancer treatment

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Johnson & Johnson secures US FDA priority review for prostate cancer treatment

Johnson & Johnson secured a priority review from the U.S. Food and Drug Administration for apalutamide to treat men with a form of prostate cancer.

The FDA expects to deliver a decision on the application by April 2018.

Priority review ensures that the FDA takes action upon an application within six months of submission, as compared to the 10-month period for standard reviews.

Apalutamide is an investigational oral androgen receptor inhibitor for treating men with nonmetastatic castration-resistant prostate cancer. There are no FDA-approved treatments for the condition.

The company submitted the application in October.